Verismo Therapeutics Announces $7 Million Pre-Series A With Brv Capital Management As Lead Investor
Feb 28, 2023•almost 3 years ago
Amount Raised
$7 Million
Round Type
pre-series a
PhiladelphiaBiotechnologyInvestors
Ignite InnovationBrv CapitalSt PharmaceuticalBrv Capital Management
Description
Verismo Therapeutics, a clinical-stage CAR T company, Penn spinout, and pioneer of the novel KIR-CAR platform technology, today announced a $7M pre-Series A financing round. The financing will support continued advancement of the clinical trial for SynKIR-110TM, a first-in-class KIR-CAR T cell immunotherapy candidate for solid tumors, and pre-clinical development of SynKIR-310, a KIR-CAR T cell immunotherapy therapeutic for blood cancer.
Funding Insights
Based on industry dataVC-backed spending patterns
VC-backed companies spend 89% more on sales and 100% more on marketing than bootstrapped peers